Akari Therapeutics Plc (AKTX)
2025-06-30 | ||||
|---|---|---|---|---|
| Foreign currency translation adjustment | -333 | |||
| Total other comprehensive (loss) income, net of tax | -333 | |||
| General and administrative | 2,452 | |||
| Restructuring and other costs | - | |||
| Research and development | 667 | |||
| Merger-related costs | - | |||
| Loss from operations | -3,119 | |||
| Other expense, net | - | |||
| Interest income | - | |||
| Interest expense | 50 | |||
| Foreign currency exchange gain (loss), net | -50 | |||
| Change in fair value of warrant liabilities | 134 | |||
| Gain on settlement of current liabilities | 1,190 | |||
| Total other income (expense), net | 1,224 | |||
| Net loss | -1,895 | |||
| Total comprehensive loss | -2,228 | |||
| Net loss per share - basic | - | |||
| Net loss per share - diluted | - | |||
| Weighted-average number of ordinary shares used in computing net loss per share - basic | 62,943,895,665 | |||
| Weighted-average number of ordinary shares used in computing net loss per share - diluted | 62,943,895,665 | |||